Disruptive Therapeutics.
Advancing Science.
Making a Difference.


Compelling preclinical study results

Preclinical studies have shown that SBP-101 produces superior anti-tumor activity in human cancer cell lines compared to gemcitabine or nab-paclitaxel, alone or in combination, standard of care chemotherapy drugs used to treat pancreatic cancer.

Sun BioPharma’s novel approach

The Company believes that SBP-101 will have a distinct advantage over current pancreatic cancer* therapies in that it specifically targets the exocrine pancreas and can cause ablation, or pharmaceutical resection, of the acinar cells, as well as the primary and metastatic pancreatic cancer, while leaving the insulin-producing islet cells and most non-pancreatic tissue unharmed.  Most current cancer therapies (including chemotherapy, radiation or surgery) are associated with significant side effects that further reduce the patient’s quality of life. Read More »
*pancreatic ductal adenocarcinoma

Compound & Clinical Targets



pancreatic cancer

Pancreatic Cancer


Michael Cullen, MD, MBA

President and Chief Executive Officer and Chairman of the Board

Read more

Susan Horvath

Vice President and Chief Financial Officer

Read more

Suzanne Gagnon, MD

Chief Medical Officer

Read more

Tammy Groene

VP of Operations

Read more

Thomas Neenan, Ph.D.

Chief Scientific Officer

Read more

Board of Directors

Read more

Sun BioPharma, Inc. is not and has never been affiliated with SUN PHARMA® and/or Sun Pharmaceutical Industries, Ltd.